All In MedTech

Device Trial Radar · NCT07272720

PMCF Investigation of MODULITH® SLX-F2 With StorM-Track in Patients With Kidney Stones

Post-Market Clinical Follow-Up Investigation of MODULITH® SLX-F2 With StorM-Track in Patients With Kidney Stones - A Confirmatory Parallel-Group, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Dec 11, 2025

Primary completion

Dec 2027

Study completion Oct 2028

Sponsor

Lead sponsor
Storz Medical AGNot on our public-company list
Sponsor type
Industry
Collaborators
Karolinska University Hospital
First posted
Dec 9, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Extracorporeal shockwave lithotripsy (ESWL) is a non-invasive standard treatment for kidney stones. This study will be conducted to evaluate the effectiveness of ESWL using MODULITH® SLX-F2 with stone tracking, compared to MODULITH® SLX-F2 without stone tracking, in adult patients with kidney stones, as measured by stone-free status.

Conditions

  • Kidney Stones
  • Urolithiasis

Interventions

  • ESWL with kidney stone tracking (StorM-Track)Device

    Starting ESWL on a low energy setting with stepwise ramping and at a frequency of 1.0 or 1.5 Hz. Up to a maximum of 3'500 shockwaves unless there is no stone visible in X-ray imaging. If fragments \> 4mm remain after the first ESWL treatment, a 2nd ESWL will be performed.

  • Standard ESWL without stone tracking (StorM-Track disabled)Device

    Same treatment protocol as for the intervention group. If fragments \> 4mm remain after the first ESWL treatment, a 2nd ESWL will be performed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stone-free rate (SFR)Time frame: 6±2 weeks post 1st treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Karolinska University Hospital

    Stockholm, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.